• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 11, 2012

View Archived Issues

Liver Transplantation, Molecular Motors Receive Lasker Awards

The newest advertising blitz of caffeinated-drug company Starbucks comes in the form of encouraging readers to share their favorite fall moments, with the Pumpkin Spice Latte featuring prominently, in tweets that include the hashtag #itsfallwhen. Read More

Imetelstat Implodes in Breast Cancer Trial, Geron Swoons

The melancholy on the Geron Corp. conference call early Monday morning was palpable after the company disclosed its decision to halt the Phase II study of imetelstat in metastatic HER2-negative breast cancer after an unplanned interim analysis revealed a greater number of deaths in the treatment arm than the comparator arm. Read More

Zalicus Shifts Gears to Pain After Phase IIb Miss in RA

Zalicus Inc., of Cambridge, Mass., is immediately terminating its development program for Synavive after a Phase IIb trial in rheumatoid arthritis failed to show meaningful clinical benefit compared to prednisolone, the active glucocorticoid component of the drug. Read More

TauRx Launches Pivotal LMTX Program in Pick's, Alzheimer's

LONDON – TauRx Therapeutics Ltd. announced the start of a 180-patient Phase III trial of its tau aggregation inhibitor, LMTX, in Pick's disease, an early onset form of dementia that shows similar characteristics to Alzheimer's disease. Read More

Financings Roundup

• Regulus Therapeutics Inc., of La Jolla, Calif., set terms for its initial public offering (IPO), planning to raise $50 million by offering 4.5 million shares in the price range of $10 to $12. Read More

Other News To Note

• Arsanis Biosciences GmbH, of Vienna, Austria, said it received two grants involving the Austrian Research Promotion Agency (Osterr. Forschungsforderungs GmbH, or FFG) to support development of monoclonal antibody drugs against nosocomial infections. Read More

Stock Movers

Read More

Clinic Roundup

• Palatin Technologies Inc., of Cranbury, N.J., said the last patient completed treatment in its Phase IIb study testing melanocortin agonist bremelanotide in female sexual dysfunction, and top-line data are expected in the first half of next quarter. The study enrolled about 400 premenopausal women, diagnosed with female sexual arousal disorder, hypoactive sexual desire disorder or both, and is designed to test subcutaneous doses of the drug intended for on-demand use. Read More

Pharma: Other News To Note

• ALK-Abello A/S, of Horsholm, Denmark, said it inked a co-promotion deal with MSD (known as Merck & Co. Inc., of Whitehouse Station, N.J., in the U.S. and Canada) for Grazax, a fast-dissolving, once-daily allergy immunotherapy for home treatment of grass pollen allergy in France. Read More

Pharma: Clinic Roundup

• Merck & Co. Inc., of Whitehouse Station, N.J., reported data from the two-month discontinuation phase of its 12-month study showing that patients who stopped taking insomnia drug suvorexant, following daily use for one year, experienced a return of their sleeping difficulties similar to those who received placebo, while adverse events were generally consistent with those reported during the 12-month study. Read More

ICAAC Roundup

• Evolva Holding SA, of Reinach, Switzerland, presented preclinical data showing that EV-035 demonstrated a broad spectrum of activity in in vitro and in vivo studies against bacteria, including those resistant to older generations of antibiotics. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • DNA double helix under a magnifying glass

    23andme genetic privacy concerns garner Congressional scrutiny

    BioWorld MedTech
    The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe